Grants8 logo Grants8
Login Create account

Grants8

Search for grants with us!

Keywords

You can filter by below criteria

Grants

Grants you might be eligible for

Grant Information Key Details Eligibility & Funding

Commercial Fishing Occupational Safety Research Cooperative Agreement (U01)

RFA-OH-22-005

Programme: Centers for Disease Control and Prevention (CDC) / National Institute for Occupational Safety and Health (NIOSH)

This grant aims to fund research projects focused on improving the occupational safety of workers within the commercial fishing industry. It is specifically designed for organizations and individuals with expertise in this field. Target Recipients
  • Individuals in academia
  • Non-profit organizations
  • Businesses involved in fishing and maritime matters
  • Other entities that possess expertise in commercial fishing safety
Sector Focus This is a SECTOR-SPECIFIC grant, exclusively targeting the commercial fishing industry and related maritime safety research. Geographic Scope The primary geographic focus is the U.S., given the involvement of U.S. federal agencies (CDC, NIOSH, U.S. Coast Guard) and the reliance on U.S. legislation. Program Context This funding opportunity is a reissue of a previous grant (RFA-OH-20-002) and offers multiple application deadlines over several years (extending into 2027), indicating a recurring program or a long-term funding initiative.

Funding

Up to 975000.00 USD

Deadline

Jan. 26, 2027, 10 p.m.

Details

NIDCD Research Grants for Translating Basic Research into Clinical Practice (R01 Clinical Trial Optional)

RFA-DC-25-002

Programme: NIH

Grant Purpose and Target
  • Clear core objective: To translate peer-reviewed and published basic research findings into practical clinical applications for better human health, specifically addressing disorders of hearing, balance, smell, taste, voice, speech, and language.
  • Explicit identification of target recipient type and size: The grant targets a wide range of organizations, including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities.
  • MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Healthcare/Biomedical Research, specifically communication disorders).
  • Geographic scope and any location requirements: Open to domestic (U.S.) and international (non-U.S.) entities. Foreign components of U.S. organizations are also eligible.
  • Key filtering criteria for initial grant screening:
  • Focus on translational research within NIDCD's mission areas.
  • Must be based on published basic research findings.
  • Project must have clear, near-term clinical impact.
  • Projects should be milestone-driven.
  • Excludes high-risk clinical trials, basic discovery research, and projects solely on underlying disease mechanisms.
  • Grant frequency and program context: This is a recurring grant, reissued from previous announcements (e.g., RFA-DC-22-001), indicating a continued program priority of the NIDCD within the NIH.

Funding

Up to 2500000.00 USD

Deadline

Oct. 12, 2027, 9 p.m.

Details

Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)

PAS-25-073

Programme: National Institutes of Health (NIH) Grants and Funding

Primary objective: Stimulate basic, translational, and clinical HIV/AIDS research within the specific mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), aligning with NIH HIV/AIDS research priorities. - Target recipient type: Primarily research institutions, non-profit organizations, for-profit entities (including small businesses), and various government bodies. - Target size: Open to diverse organizational sizes, from small businesses to large higher education institutions; size not defined by specific employee counts. - SECTOR-SPECIFIC - Geographic scope: Open to entities located in the U.S. and non-U.S. (foreign) organizations. - Key filtering criteria: Research must specifically focus on HIV/AIDS topics within NIDDK's mission areas (e.g., diabetes, GI, liver, kidney, hematologic diseases) and align with current NIH HIV/AIDS research priorities. Clinical trials are optional. - Grant frequency: This is a recurring funding opportunity, a reissue of a previous call, with multiple application submission windows spanning several years until January 2028. - Program context: This grant is part of a broader federal initiative by the National Institutes of Health (NIH) to address HIV/AIDS through targeted scientific inquiry, leveraging NIDDK's specialized research focus.

Funding

Up to None USD

Deadline

Jan. 7, 2028, 5 p.m.

Details

BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)

RFA-MH-26-120

Programme: NIH BRAIN Initiative

This grant, part of the NIH BRAIN Initiative, aims to support facilities at Resource-Limited Institutions (RLIs) and Institutional Development Award (IDeA)-eligible institutions for the scaled production and distribution of brain cell type-specific access reagents. The core objective is to broaden the availability of these enabling neurotechnologies to the wider neuroscience community, thereby enhancing research infrastructure at under-resourced institutions. This is a SECTOR-SPECIFIC grant focused on biomedical research, specifically neuroscience and neurotechnologies. The target recipients are diverse U.S.-based organizations that meet the criteria of being an RLI or an IDeA-eligible institution. This funding opportunity is a reissue, indicating a recurring program context within the BRAIN Initiative.

Funding

Up to None USD

Deadline

June 15, 2027, 5 p.m.

Details

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)

RFA-DA-26-056

Programme: National Institutes of Health (NIH) - National Institute on Drug Abuse (NIDA)

This grant aims to accelerate substance use research by funding innovative analysis of existing social science, behavioral, administrative, and neuroimaging data. It focuses on understanding the etiology, epidemiology, prevention, and treatment of substance use and related disorders, including HIV. The grant targets research institutions and organizations with strong data analysis capabilities. - Target recipient type: Research institutions, non-profits, for-profit organizations, and government entities capable of sophisticated data analysis. - Target size: Not explicitly limited by size; open to various organizational structures. - SECTOR-SPECIFIC: Healthcare, Public Health, Social Science Research. - Geographic scope: Domestic (U.S.) and non-U.S. (Foreign) entities are eligible to apply. - Key filtering criteria: Focus on existing data analysis, no primary data collection, and relevance to substance use/HIV. - Grant frequency: Recurring (reissue of a previous RFA) with multiple application cycles through December 2027. - Program context: Part of NIH's broader effort to advance knowledge and approaches for substance use prevention, diagnosis, and treatment.

Funding

Up to 275000.00 USD

Deadline

Dec. 3, 2027, 5 p.m.

Details

Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)

PAR-25-230

Programme: National Institutes of Health (NIH)

  • Core Objective: This grant aims to support time-sensitive ancillary studies that leverage existing clinical projects (parent projects) to enhance scientific understanding related to the NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) mission.
  • Target Recipient: A broad range of organizations capable of conducting research, including higher education institutions, non-profits, for-profit entities, and various governmental bodies.
  • SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on biomedical and biobehavioral research within clinical studies, aligned with the NIAMS mission.
  • Geographic Scope: Only organizations located within the United States or its territories/possessions are eligible.
  • Key Filtering Criteria: Applicants must propose an ancillary study that is truly 'time-sensitive' and can efficiently leverage an ongoing, independently funded clinical parent project. The project must not involve a new clinical trial. Non-time-sensitive projects or those that do not align with the NIAMS mission are excluded.
  • Grant Frequency and Program Context: This is a recurring funding opportunity (reissue of a previous PAR) within the NIH's R21 Exploratory/Developmental Research Grant program.

Funding

Up to 400000.00 USD

Deadline

Dec. 5, 2025, 5 p.m.

Details

Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)

PAR-25-229

Programme: National Institutes of Health (NIH)

This grant, 'Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)', aims to foster novel, investigator-initiated research in computational genomics, data science, statistics, bioinformatics, and data visualization/exploration. It supports the development of innovative analytical methodologies, approaches, and early-stage tools/software broadly applicable to human health and disease. - Target recipient type: Diverse organizational types including academic institutions, nonprofits, for-profit organizations (small and large businesses), and various government entities. - Target size: Not specifically defined by size, but supports a wide range of eligible organizations. - SECTOR-SPECIFIC: Genomics, Data Science, Bioinformatics. - Geographic scope: Organizations from the U.S. and non-U.S. (foreign) entities are eligible to apply. - Key filtering criteria: Projects must be highly innovative, focus on novel approaches, and explicitly exclude clinical trials, microbial genomics, maintenance of existing resources, non-generalizable research, and basic data science not tied to genomics. - Grant frequency and program context: This is a recurring funding opportunity, a reissue of a previous announcement (PAR-21-255), with multiple application due dates extending through 2027.

Funding

Up to 275000.00 USD

Deadline

July 16, 2027, 10 p.m.

Details

Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

PAR-25-064

Programme: National Institutes of Health (NIH) - Exploratory/Developmental Research Grant (R21)

This grant aims to support research that enhances the understanding of mechanisms underlying neuropsychiatric symptoms (NPS) in individuals with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The goal is to advance mechanistic understanding of biobehavioral and neurobiological pathways to identify novel therapeutic targets for treating and preventing NPS. - Target recipients: Research institutions including universities, non-profits, for-profit organizations (including small businesses), and government entities. - SECTOR-SPECIFIC: Focuses on biomedical, behavioral, and social sciences research related to Alzheimer's and dementias. - Geographic scope: Open to domestic (U.S.) and non-domestic (non-U.S.) entities (foreign organizations). - Key filtering criteria: Focus on mechanistic research for NPS in AD/ADRD, clinical trial optional (R21 mechanism for high-risk/high-reward projects lacking extensive preliminary data). - Grant frequency: Recurring (reissue of previous PARs), with multiple submission dates through September 2026.

Funding

Up to 275000.00 USD

Deadline

June 16, 2026, 5 p.m.

Details

Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required)

PA-24-189

Programme: NIH Research Career Development program

This grant, the Midcareer Investigator Award in Patient-Oriented Research (K24), aims to support mid-career health-professional doctorates by providing them with dedicated time to conduct patient-oriented research (POR). A key objective is for these senior researchers to act as mentors for junior clinical investigators entering POR. This is a sector-specific grant, focused on biomedical, behavioral, and clinical research needs. It targets individual investigators within eligible U.S. organizations (higher education, non-profits, government, and some for-profits). The program is recurring, reissuing a previous announcement, and falls under the broader NIH Research Career Development program.

Funding

Up to None USD

Deadline

Feb. 12, 2027, 5 p.m.

Details

Robust and trustworthy GenerativeAI for Robotics and industrial automation (RIA) (AI/Data/Robotics & Made in Europe Partnerships)

48401116TOPICSen

Programme: Horizon Europe

Grant Purpose and Target
  • Core Objective: To develop robust and trustworthy Generative AI solutions specifically for robotics and industrial automation, aiming to boost productivity and competitiveness within the European manufacturing sector.
  • Target Recipient Type and Size: Primarily organizations engaged in advanced Artificial Intelligence (AI) research and industrial application. This includes businesses of various sizes, with a focus on those that can collaborate with or support the manufacturing industry, including SMEs and startups as third-party recipients.
  • Designation: SECTOR-SPECIFIC (Manufacturing, Robotics, Artificial Intelligence).
  • Geographic Scope: Open to legal entities established in EU Member States, Iceland, Norway, Canada, Israel, the Republic of Korea, New Zealand, Switzerland, and the United Kingdom.
  • Key Filtering Criteria: Focus on Generative AI, robotics, industrial automation, and projects that contribute to the EU's strategic autonomy in digital technologies.
  • Grant Frequency and Program Context: This is a single-stage call within the Horizon Europe Work Programme 2025, specifically under 'Digital, Industry and Space'. It is part of the broader GenAI4EU initiative and aligns with the AI, Data, and Robotics (ADRA) and Made in Europe European Partnerships.

Funding

Up to 45000000.00 EUR

Deadline

Oct. 2, 2025, midnight

Details

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

RFA-DA-26-034

Programme: Chemical Countermeasures Research Program (CCRP)

  • The grant's core objective is to support basic research aimed at understanding and mitigating the harmful and lethal effects of acute exposure to Ultra-Potent Synthetic (UPS) opioids and their combinations, as well as their persistent or delayed health impacts.
  • Target recipients are diverse U.S.-based organizations engaged in scientific research.
  • This is a SECTOR-SPECIFIC grant, focused on medical and public health research related to chemical countermeasures and toxicology.
  • Geographic scope is limited to U.S. organizations; foreign entities are not eligible to apply, although foreign components of U.S. organizations may be allowed.
  • Key filtering criteria include a focus on specific DHS Chemicals of Concern (CoC) within the opioid category, and the exclusion of clinical trials, pain management, or substance use disorder treatment research.
  • This is a recurring grant opportunity, being a reissue, and part of the broader Chemical Countermeasures Research Program (CCRP) within NIH.

Funding

Up to 300000.00 USD

Deadline

Nov. 18, 2027, 10 p.m.

Details

EIC pre-accelerator - Widening

48351397TOPICSen

Programme: Horizon Europe

- - The core objective of this grant is to increase the innovation potential of deep-tech startups in 'Widening Countries' and enhance their ability to attract private investments and scale up. - The primary target recipients are deep-tech startups which are classified as 'Small and Medium Enterprises' (SMEs). - This is a SECTOR-SPECIFIC grant, exclusively focused on deep-tech innovation. - The geographic scope is limited to 'Horizon Europe Widening Countries'. - Key filtering criteria include being a deep-tech SME located in a Widening country, possessing high-impact innovation, and demonstrating a clear ambition to scale. - The grant is part of the EIC pre-accelerator program within Horizon Europe, suggesting a recurring call within the broader framework.

Funding

Up to 500000.00 EUR

Deadline

Nov. 18, 2025, midnight

Details

NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-25-141

Programme: National Institutes of Health (NIH) - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

The core objective of this grant is to fund the implementation of investigator-initiated, single or multi-site, interventional clinical trials (all phases). The trials must focus on the prevention or treatment of rheumatic, musculoskeletal, or skin diseases or disorders, aligning with the research mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). - Target recipient type and size: The grant targets a wide range of U.S.-based organizations including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities. - SECTOR-SPECIFIC: This grant is highly sector-specific, focusing exclusively on clinical trials related to arthritis, musculoskeletal, and skin diseases. - Geographic scope and any location requirements: Applicant organizations must be based in the U.S. However, foreign components (e.g., international clinical sites) are allowed within the trial design, meaning the research itself can have an international reach. - Key filtering criteria for initial grant screening: Applicants must propose an NIH-defined clinical trial, not observational studies or basic experimental studies involving humans (BESH). The trial design and preparatory work must be largely complete before application. The proposed work must be within the NIAMS mission areas. - Grant frequency and program context: This is a recurring funding opportunity with multiple application due dates annually until its expiration date of March 05, 2027. It utilizes a two-phase (UG3/UH3) cooperative agreement mechanism, where the UG3 phase is for start-up activities and the UH3 phase is for full trial execution, contingent on meeting UG3 milestones.

Funding

Up to None USD

Deadline

Nov. 2, 2026, 5 p.m.

Details

Technologies for optronic detectors

EDF-2025-DA-SENS-IRD-STEP

Programme: European Defence Fund (EDF)

The core objective of this grant is to enhance the technological maturity of advanced Read-Out Integrated Circuits (ROICs) for Infrared (IR) detectors and fully qualify their supply chain for defence systems. The grant targets 'EU IR detector developers' and 'main EU IR detector providers' who must collaborate. This is a SECTOR-SPECIFIC grant focused on defence and optronics technology within EU Member States and EDF Associated Countries. Key filtering criteria include a focus on next-generation IR detector ROICs and the mandatory requirement for a collaborative consortium.

Funding

Up to None EUR

Deadline

Oct. 16, 2025, midnight

Details

Fighting against discrimination and racism, xenophobia and other forms of intolerance, including antigypsyism, anti-black, and anti-Asian racism

48585039TOPICSen

Programme: Citizens, Equality, Rights and Value Programme (CERV)

This grant aims to combat all forms of discrimination, racism, xenophobia, and intolerance, with a specific focus on antigypsyism, anti-black racism, and anti-Asian racism. It is a SECTOR-SPECIFIC grant within the social domain, primarily targeting organizations working on equality and human rights. The exact target recipient types and sizes are not explicitly defined in the provided materials, but 'public entities' are noted as eligible. While specific eligible countries are not listed in the provided information, the grant is offered under the EU's CERV Programme, indicating a general focus on EU Member States. This call for proposals is part of the multi-annual CERV Programme (2021-2027), making it a recurring program.

Funding

Up to None EUR

Deadline

Oct. 23, 2025, 3 p.m.

Details

The impact of pollution on the development and progression of brain diseases and disorders

HORIZON-HLTH-2025-03-ENVHLTH-01-two-stage

Programme: Horizon Europe - Cluster 1: Health

This grant aims to support research and innovation activities that explore the impact of pollution on the development and progression of brain diseases and disorders. The core objective is to generate scientific evidence, tools, and methodologies that can inform global and EU policies, protect citizens, and provide open access to data on this critical link. It is specifically targeted at research institutions, universities, public bodies, and private companies (including SMEs and larger enterprises) capable of conducting in-depth scientific research. This is a SECTOR-SPECIFIC grant focusing on the Health and Environment sectors, particularly in areas related to neurobiology, public health, and occupational medicine. Geographically, the grant is open to organizations established in EU Member States, Associated Countries to Horizon Europe, and the United States of America. Key filtering criteria for initial screening include a strong focus on brain diseases and their link to environmental pollution, the capacity for high-quality scientific research, and the willingness to participate in a consortium and contribute to common networking activities. This grant is part of the recurring Horizon Europe Work Programme 2025, indicating it is a regular funding opportunity within the 2021-2027 framework.

Funding

Up to 7000000.00 EUR

Deadline

April 16, 2026, midnight

Details

Advancing knowledge on the impacts of micro- and nanoplastics on human health

HORIZON-HLTH-2025-03-ENVHLTH-02-two-stage

Programme: Horizon Europe

This grant, 'Advancing knowledge on the impacts of micro- and nanoplastics on human health,' aims to deepen our understanding of how micro- and nanoplastics (MNPs) affect human health. The core objective is to support research that provides robust scientific evidence to inform environmental and health policies, prevent adverse health impacts, and protect citizens' well-being from MNP exposure. This is a SECTOR-SPECIFIC grant primarily targeting the healthcare and environment research sectors. Target Recipients This funding opportunity is designed for research organizations, universities, public bodies, and potentially industry players (SMEs, enterprises) engaged in health and environmental research. It emphasizes collaborative efforts, requiring applicants to form a consortium. Geographic Scope The grant is open to entities established in EU Member States, Associated Countries (under Horizon Europe rules), and explicitly, the United States of America. Key Filtering Criteria To be a good fit, your project should: * Focus directly on the human health impacts of micro- and nanoplastics. * Propose Research and Innovation Actions (RIA), meaning a strong research component. * Be prepared to apply as part of a consortium. * Understand and comply with the two-stage application process and the blind evaluation pilot for the first stage. Grant Program Context This topic is part of the Horizon Europe, Health Cluster (Cluster 1) for 2025, specifically under the destination 'Living and working in a health-promoting environment'. While this specific topic is for the 2025 Work Programme, Horizon Europe is a multi-annual framework, suggesting that similar environmental health topics may recur in future years.

Funding

Up to 8000000.00 EUR

Deadline

April 16, 2026, midnight

Details

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)

PAR-25-266

Programme: National Institutes of Health (NIH) - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

This grant, PAR-25-266, from the National Institutes of Health (NIH) through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), aims to fund exploratory or novel research projects (R21 activity code) focused on developing new screening methods or treatments for conditions that are part of newborn screening programs or could be added in the near future. The grant is SECTOR-SPECIFIC, targeting healthcare and research. It's open to a wide range of U.S. and international organizations, seeking to improve early detection and intervention for potentially fatal or disabling genetic conditions in newborns. This is a recurring funding opportunity.

Funding

Up to 275000.00 USD

Deadline

Nov. 16, 2027, 5 p.m.

Details

Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)

PAR-25-291

Programme: National Institutes of Health (NIH)

The core objective of this grant is to encourage research utilizing invasive neural recording and stimulation in humans to advance the understanding of neural circuitry related to mental health disorders. It aims to fill a gap in scientific knowledge regarding neural circuit function and has high translational potential for mental health.
  • Target recipient types: A wide range of organizations including higher education institutions, non-profits, for-profit organizations (including small businesses), and various government entities.
  • Target size: SECTOR-AGNOSTIC regarding organizational size, focusing more on research capacity and team expertise.
  • Geographic scope: Global; foreign organizations are explicitly eligible to apply.
  • Key filtering criteria: Research must involve invasive neural recording and/or stimulation in human subjects, focus on mental health questions with high translational potential, and include neuroethical considerations.
  • Grant frequency: This is a recurring opportunity with multiple application deadlines through October 2027, issued as a reissue of a previous funding opportunity (PAR-23-101).

Funding

Up to 275000.00 USD

Deadline

Nov. 16, 2027, 5 p.m.

Details

NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)

PAR-24-321

Programme: National Institutes of Health (NIH) - National Institute on Aging (NIA) Career Development Program

This grant, the NIA Academic Leadership Career Award (K07), aims to support established investigators who possess the expertise and leadership necessary to enhance aging and/or Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) research capacity within their academic institutions. The core objective is to develop crucial research and educational infrastructure, mentorship programs, and career development activities to advance new or emerging areas in these fields. This is a SECTOR-SPECIFIC grant, focusing primarily on healthcare and biomedical research related to aging and dementia. The geographic scope is limited to U.S.-based organizations and their components; foreign entities are not eligible. Key filtering criteria for initial screening include the applicant's status as an established investigator with an active R01-equivalent NIA grant or multi-component sub-project, and the institution's strong research environment. This is a recurring grant program with multiple application cycles, representing a reissue of a previous funding opportunity to align with current agency priorities.

Funding

Up to 750000.00 USD

Deadline

Nov. 12, 2027, 5 p.m.

Details

992 results. Page 38 of 50.